Publications
Publications
Show Results For
- All HBS Web
(1,287)
- Faculty Publications (521)
- January 1993 (Revised April 1993)
- Case
Chadwick, Inc.: The Balanced Scorecard
By: Robert S. Kaplan
The pharmaceutical division of a diversified company has been asked to develop a Balanced Scorecard. Research and development projects take about ten years to bring a new product to the marketplace and the division depends on good relations and active feedback from its... View Details
- December 1992 (Revised September 1996)
- Case
ImmuLogic Pharmaceutical Corporation (Abridged)
By: Josh Lerner
ImmuLogic Pharmaceutical Corp., a development-stage biotechnology company, is considering making an initial offering of common stock. The rationales for and problems of high-technology start-ups are explored. The challenges posed by "windows" for public offerings are... View Details
- October 1992 (Revised September 1993)
- Case
Nopane Advertising Strategy
By: David E. Bell
Nopane is a proprietary drug that sells in much of the United States. It faces substantial competition. The brand manager is undertaking an experiment to determine whether ad copy should be emotional-based or rational-based. The data and associated regression results... View Details
- October 1992 (Revised November 1997)
- Case
ImmuLogic Pharmaceutical Corporation (A): March 1991
By: Josh Lerner
ImmuLogic Pharmaceutical Corp., a development-stage biotechnology company, is considering making an initial offering of common stock. The diverse perspectives of the entrepreneur, venture capitalist, investment banker, and institutional investor are explored. Problems... View Details
- October 1992 (Revised March 1993)
- Supplement
ImmuLogic Pharmaceutical Corporation (B1): Malcolm Gefter
By: Josh Lerner
Supplements the (A) case. View Details
Keywords: Pharmaceutical Industry
- October 1992 (Revised April 1993)
- Supplement
ImmuLogic Pharmaceutical Corporation (B2): Henry McCance
By: Josh Lerner
Supplements the (A) case. View Details
Keywords: Pharmaceutical Industry
- October 1992 (Revised March 1993)
- Supplement
ImmuLogic Pharmaceutical Corporation (B3): Katherine Kirk
By: Josh Lerner
Supplements the (A) case. View Details
Keywords: Pharmaceutical Industry
- October 1992 (Revised April 1993)
- Supplement
ImmuLogic Pharmaceutical Corporation (B4): Phillip Gross
By: Josh Lerner
Supplements the (A) case. View Details
Keywords: Pharmaceutical Industry
- October 1992 (Revised March 1993)
- Supplement
ImmuLogic Pharmaceutical Corporation (C): April 1991
By: Josh Lerner
Supplements the (A) case. View Details
Keywords: Pharmaceutical Industry
- May 1992
- Teaching Note
Amgen, Inc.: Planning the Unplannable, Teaching Note
By: Nitin Nohria
Teaching Note for (9-492-052). View Details
Keywords: Pharmaceutical Industry
- May 1992
- Teaching Note
RU 486 (A) and (B), Teaching Note
Teaching Note for (9-391-050) and (9-391-051). View Details
- March 1992
- Case
Amgen, Inc.: Planning the Unplannable
By: Nitin Nohria
By the early 1990s, Amgen--a pharmaceutical company started little over a decade ago as Applied Molecular Genetics--was within range of becoming a billion-dollar company. With two extremely successful biotechnology drugs on the market, Amgen stood as the largest and... View Details
- February 1992 (Revised April 1995)
- Case
Pfizer: Global Protection of Intellectual Property
By: Lynn S. Paine and Michael Santoro
Top officials at Pfizer are assessing their strategy for improving protection of Pfizer's patents around the world. The outcome of the Uruguay Round of the GATT negotiations is uncertain, and it is not clear whether an acceptable intellectual property protection... View Details
- January 1992
- Teaching Note
Advanced Medical Technology Corporation TN
By: Thomas R. Piper
Teaching Note for (9-287-028). View Details
Keywords: Pharmaceutical Industry
- September 1991 (Revised August 1994)
- Background Note
Note on Pharmaceutical Industry Regulation
Traces the evolution of U.S. regulatory policy towards the pharmaceutical industry over the course of the twentieth century. A major theme is the steady shift away from a policy of 'let the buyer beware' to the creation of a complex and time-consuming review process,... View Details
- September 1991 (Revised February 1993)
- Case
Burroughs Wellcome and AZT (A)
Burroughs Wellcome Co., developer of AZT, the first drug approved by the U.S. Food and Drug Administration for the treatment of Acquired Immune Deficiency Syndrome (AIDS), finds itself under siege in September 1989 by AIDS activists and various segments of the U.S.... View Details